Elahere Fully Approved for Certain Ovarian, Fallopian Tube or Primary Peritoneal Cancer

The FDA approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult patients with FRalpha-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Patients are selected based on an FDA-approved test. Mirvetuximab soravtansine-gynx previously received accelerated approval for this indication.

Efficacy was evaluated in Study 0416 (MIRASOL,